Johnson & Johnson Supports HRS Registry for PFA Data Collection

Key highlights

Introduction

Johnson & Johnson MedTech has announced its sponsorship of a new data collection platform developed by the Heart Rhythm Society (HRS). This platform is designed to capture real-world data on pulsed field ablation (PFA) procedures used to treat atrial fibrillation (AFib).

Registry Objectives

The registry aims to serve as a long-term data collection platform to evaluate clinical outcomes, support evidence-based practice, and inform the evolution of treatment strategies in electrophysiology.

Company Commitment

Johnson & Johnson MedTech is committed to advancing the science of PFA and driving progress in arrhythmia care. This is part of their broader effort to enhance healthcare through rigorous scientific inquiry and clinical excellence in electrophysiology.

Technological Integration

The company offers a comprehensive portfolio of imaging, mapping, and ablation technologies, including versatile PFA platforms, designed to deliver safe, precise, and consistent outcomes across a wide range of patient needs.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

19 June 2026
Johnson & Johnson: MEMBRANE shows MMA embolization with TRUFILL n‑BCA reduces cSDH recurrence

Randomized MEMBRANE trial found adding middle meningeal artery embolization with TRUFILL n‑BCA to standard care lowered chronic subdural hematoma recurrence and re‑intervention.

13 April 2026
Johnson & Johnson reports positive 12‑month VARIPULSE results at EHRA 2026

12‑month post‑market study: 84.2% freedom from atrial arrhythmia (90.5% paroxysmal; 75.3% persistent); 0.8% primary adverse events; CE‑mark allows ablation beyond pulmonary veins

18 December 2025
Johnson & Johnson's TRUFILL n-BCA Approved by FDA for Chronic Subdural Hematoma Treatment

FDA approves TRUFILL n-BCA for MMA embolization in chronic subdural hematoma, offering a minimally invasive alternative to surgery with proven safety and effectiveness.

3 November 2025
Johnson & Johnson Validates IVL Durability in Complex BTK Cases at VIVA 2025

DISRUPT BTK II study shows IVL's effectiveness in treating calcified lesions, reducing amputations, and improving quality of life for PAD patients.

27 October 2025
Johnson & Johnson MedTech Advances AI in Surgery

The Polyphonic AI Fund supports AI-driven surgical innovations, awarding Mayo Clinic and QAS.AI for projects enhancing surgical precision and decision-making.